News - Onconova Therapeutics, Baxter International

Filter

Popular Filters

1 to 25 of 32 results

Baxter to acquire Chatham Therapeutics for $70 million

03-04-2014

USA-based Baxter International says it has agreed to acquire Chatham Therapeutics, a private biotechnology…

Baxter InternationalBiotechnologyChatham TherapeuticsHematologyMergers & Acquisitions

Baxter to split, creating two separate health care companies

Baxter to split, creating two separate health care companies

28-03-2014

News that USA-based Baxter International plans to create two separate, independent global health care…

Baxter InternationalManagementMergers & AcquisitionsPharmaceutical

Onconova tanks, as lead drug rigosertib fails in Ph III MDS study

Onconova tanks, as lead drug rigosertib fails in Ph III MDS study

21-02-2014

US biotech firm Onconova Therapeutics saw its shares plunge 37% to $8.70 in pre-market trading yesterday…

Baxter InternationalOncologyOnconova TherapeuticsPharmaceuticalResearchrigosertib

Baxter restructures deal with Xenetic Biosciences

31-01-2014

USA-based Baxter International has restructured its ongoing agreement with Xenetic Biosciences for the…

BAX 826Baxter InternationalHematologyLicensingPharmaceuticalResearchXenetic Biosciences

Baxter’s Feiba gains FDA approval for prophylactic treatment of hemophilia A and B

Baxter’s Feiba gains FDA approval for prophylactic treatment of hemophilia A and B

20-12-2013

US drugmaker Baxter International has received approval from the US Food and Drug Administration for…

Baxter InternationalFeibaHematologyPharmaceuticalRegulation

Onconova drops Ph III trial of rigosertib in pancreatic cancer

20-12-2013

US biopharma company Onconova Therapeutics says it has discontinued the Phase III ONTRAC study of intravenous…

OncologyOnconova TherapeuticsPharmaceuticalResearchrigosertib

Baxter files amended BLA to FDA for HyQvia for primary immunodeficiency

Baxter files amended BLA to FDA for HyQvia for primary immunodeficiency

02-12-2013

USA-based Baxter International has completed submission of an amended biologics license application to…

Baxter InternationalHalozyme TherapeuticsHyQviaImmunologicalsNorth AmericaPharmaceuticalRegulationUSA

Baxter buys exclusive rights to CTI’s cancer drug pacritinib

18-11-2013

USA-based companies Baxter International and Cell Therapeutics have entered into an exclusive worldwide…

Baxter InternationalCell TherapeuticsFinancialGlobalLicensingOncologypacritinibPharmaceutical

Onconova could file NDA for cancer drug rigosertib next year

Onconova could file NDA for cancer drug rigosertib next year

15-11-2013

Analysts at Edison Equity Research have indicated that US biopharma company Onconova Therapeutics (Nasdaq:…

FinancialOncologyOnconova TherapeuticsPharmaceuticalResearchrigosertibUSA

Acquisition costs take toll on Baxter’s 3rd-qtr financials

18-10-2013

USA-based Baxter International has posted solid financial results for the third quarter of 2013, showing…

Baxter InternationalFinancialHematologyPharmaceutical

Vivaldi Biosciences acquires clinical stage influenza vaccine assets

13-10-2013

Privately-held US biotech firm Vivaldi Biosciences has acquired from Baxter Healthcare R&D assets, including…

Anti-viralsBaxter HealthcareBaxter InternationalBiotechnologyMergers & AcquisitionsVaccinesVivaldi Biosciences

Baxter and Coherus in up to $246 million deal for biosimilar etanercept

04-09-2013

US companies Baxter International (NYSE:BAX) and Coherus Biosciences have entered into an exclusive collaboration…

AmgenAnti-Arthritics/RheumaticsBaxter InternationalBiotechnologyCoherus BioSciencesEnbreletanerceptGenericsLicensingResearch

EU Commission puts conditions on Baxter's acquisition of Gambro

23-07-2013

The European Commission has authorized the proposed $4 billion acquisition of privately-held Swedish…

Baxter InternationalGambroMergers & AcquisitionsPharmaceutical

Pivotal drivers for prescribing metastatic pancreatic cancer drugs: report

09-07-2013

The effect on key efficacy endpoints, primarily the effect of an emerging therapy on overall survival,…

AbraxaneBiotechnologyCelgeneEli LillyEuropeGemzarMarkets & MarketingNorth AmericaOncologyOnconova TherapeuticsPharmaceuticalrigosertib

FDA backs Baxter's Rixubis for hemophilia B; Breakthrough status for GSK's drisapersen

28-06-2013

The US Food and Drug Administration yesterday (June 27) approved Baxter International's (NYSE: BAX) Rixubis…

Baxter InternationaldrisapersenGlaxoSmithKlineNorth AmericaPharmaceuticalRare diseasesRegulationRixubis

Baxter shares dip as Alzheimer's drug fails to meet Ph III endpoints

08-05-2013

Shares of US drugmaker Baxter International (NYSE: BAX) fell 2.5% to $68.58 in New York trading on May…

Baxter InternationalGammagardNeurologicalPharmaceuticalResearch

Ipsen and Inspiration Biopharma in deal with Baxter for OBI-1

24-01-2013

French drugmaker Ipsen (Euronext: IPN) and privately-held US firm Inspiration Biopharmaceuticals have…

Baxter InternationalIB1001Inspiration BiopharmaceuticalsIpsenMergers & AcquisitionsOBI-1Pharmaceutical

GVK Biosciences and Onconova in cancer drug development deal

09-01-2013

GVK Biosciences, a Hyderabad, India-based contract research and development organization, and privately-held…

Ex-RADGVK BiosciencesON-013105OncologyOnconova TherapeuticsPharmaceuticalResearchrigosertib

Baxter to expand renal therapies range with $4 billion buy of Gambro

04-12-2012

Confirming recent rumors and speculation, Baxter International (NYSE:BAX ) said yesterday it has entered…

Baxter InternationalGambroMergers & AcquisitionsNephrology and HepatologyPharmaceutical

Baxter in up to $565 million deal with Onconova for rigosertib

20-09-2012

US companies Baxter International (NYSE: BAX) and privately-held biotech Onconova Therapeutics have entered…

Baxter InternationalEstybonEuropeLicensingOncologyOnconova TherapeuticsPharmaceuticalrigosertib

News briefs: setbacks for B-MS hep C drug; Baxter's HyQ

02-08-2012

US drug major Bristol-Myers Squibb (NYSE: BMY) has suspended study drug administration in ongoing Phase…

Anti-viralsBaxter InternationalBMS-986094Bristol-Myers SquibbHyQImmunologicalsNorth AmericaPharmaceuticalRegulationResearch

Baxter's Gammagard shows potential in stabilizing Alzheimer's

18-07-2012

The first report of long-term (three-year) stabilization of Alzheimer's disease symptoms with intravenous…

Baxter InternationalGammagardNeurologicalPharmaceuticalResearch

1 to 25 of 32 results

Back to top